title: Combined modality therapy in small cell lung cancer.
authors.forename: P
authors.initials: P
authors.lastname: Bunn
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: N
authors.initials: N
authors.lastname: Choi
authors.forename: R
authors.initials: R
authors.lastname: Feld
authors.forename: A
authors.initials: A
authors.lastname: Gregor
authors.forename: J
authors.initials: J
authors.lastname: Jett
authors.forename: B
authors.initials: B
authors.lastname: Johnson
authors.forename: R
authors.initials: R
authors.lastname: Komaki
authors.forename: P
authors.initials: P
authors.lastname: Kristjansen
authors.forename: N
authors.initials: N
authors.lastname: Murray
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000075202:Contraindications; D016371:Cranial Irradiation; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin